Raf-1 kinase inhibitor protein (RKIP) is a tumor and metastasis suppressor that promotes drug-induced apoptosis in cancer cells. It is frequently downregulated, both at the mRNA and protein level, in hepatocellular carcinoma (HCC), but the mechanisms leading to this reduction are obscure.We sequenced the whole RKIP gene in three human HCC cell lines (HA22T/VGH, HepG2, and Hep3B), and in five clinical HCC samples, but could not find any gene variant that might account for their low RKIP levels. We also examined whether gene methylation may be responsible for the altered RKIP expression. No methylation of the RKIP gene was found in the tumor samples, while among the cell lines only Hep3B showed methylation of the gene, which was reduced by tr...
Raf Kinase Inhibitory Protein or RKIP was initially identified as a Raf-1 binding protein using the ...
Hepatocellular carcinoma (HCC) is the most common liver cancer and is one of the most prevalent canc...
International audienceBACKGROUND:Therapeutic outcomes using the multikinase inhibitors, sorafenib an...
Raf-1 kinase inhibitor protein (RKIP) is a tumor and metastasis suppressor that promotes drug-induce...
Simple Summary Raf Kinase Inhibitor protein is a protein that governs multiple intracellular signall...
Raf kinase inhibitory protein (RKIP; also known as PEBP, for phosphatidylethanolamine-binding protei...
Purpose: Raf-1 kinase inhibitor protein (RKIP) was originally identified as the first physiologic in...
The Raf Kinase Inhibitor Protein (RKIP) is a unique gene product that directly inhibits the Raf/Mek/...
Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by p...
<div><p>Therapeutic resistance remains the most challenging aspect of treating cancer. Raf kinase in...
Raf Kinase Inhibitory Protein (RKIP) is a highly conserved kinase inhibitor that functions as a meta...
Loss of function of metastasis suppressor genes is an important step in the progression to a maligna...
Abstract: Raf-1 Kinase Inhibitory Protein (RKIP) belongs to a new class modulators of signalling cas...
Background: Raf kinase inhibitor protein (RKIP), an inhibi-tor of Raf-mediated activation of mitogen...
<div><p>Raf Kinase Inhibitory Protein or RKIP was initially identified as a Raf-1 binding protein us...
Raf Kinase Inhibitory Protein or RKIP was initially identified as a Raf-1 binding protein using the ...
Hepatocellular carcinoma (HCC) is the most common liver cancer and is one of the most prevalent canc...
International audienceBACKGROUND:Therapeutic outcomes using the multikinase inhibitors, sorafenib an...
Raf-1 kinase inhibitor protein (RKIP) is a tumor and metastasis suppressor that promotes drug-induce...
Simple Summary Raf Kinase Inhibitor protein is a protein that governs multiple intracellular signall...
Raf kinase inhibitory protein (RKIP; also known as PEBP, for phosphatidylethanolamine-binding protei...
Purpose: Raf-1 kinase inhibitor protein (RKIP) was originally identified as the first physiologic in...
The Raf Kinase Inhibitor Protein (RKIP) is a unique gene product that directly inhibits the Raf/Mek/...
Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by p...
<div><p>Therapeutic resistance remains the most challenging aspect of treating cancer. Raf kinase in...
Raf Kinase Inhibitory Protein (RKIP) is a highly conserved kinase inhibitor that functions as a meta...
Loss of function of metastasis suppressor genes is an important step in the progression to a maligna...
Abstract: Raf-1 Kinase Inhibitory Protein (RKIP) belongs to a new class modulators of signalling cas...
Background: Raf kinase inhibitor protein (RKIP), an inhibi-tor of Raf-mediated activation of mitogen...
<div><p>Raf Kinase Inhibitory Protein or RKIP was initially identified as a Raf-1 binding protein us...
Raf Kinase Inhibitory Protein or RKIP was initially identified as a Raf-1 binding protein using the ...
Hepatocellular carcinoma (HCC) is the most common liver cancer and is one of the most prevalent canc...
International audienceBACKGROUND:Therapeutic outcomes using the multikinase inhibitors, sorafenib an...